Last reviewed · How we verify

NCT03985527

Janus Feasibility Study

Completed NA Last updated 30 January 2026
What this trial tests

NA trial testing Transvenous nerve stimulation in Sleep Apnea Syndromes in 29 participants. Completed in 12 December 2025.

Timeline
9 January 2020
Primary endpoint
12 December 2025
12 December 2025

Quick facts

Lead sponsorRespicardia, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment29
Start date9 January 2020
Primary completion12 December 2025
Estimated completion12 December 2025
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Respicardia, Inc.

Who can join

18 and older, any sex, with Sleep Apnea Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this feasibility study is to assess whether an alternative transvenous lead location affects respiration and airway physiology during a commercial remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator) implant procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sleep Apnea Syndromes

Currently open trials in the same condition.

Other Respicardia, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03985527.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing